Is it time to widen the use of somatostatin analogs in neuroendocrine tumors?
Oberg
Kjell E
KE
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D006801:Humans; D007414:Intestinal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D015337:Multicenter Studies as Topic; D018358:Neuroendocrine Tumors / Q000188:drug therapy* / Q000473:pathology; D015282:Octreotide / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D015282:Octreotide